purvalanol-a and Bone-Diseases

purvalanol-a has been researched along with Bone-Diseases* in 1 studies

Other Studies

1 other study(ies) available for purvalanol-a and Bone-Diseases

Article	Year
Bone-targeted 2,6,9-trisubstituted purines: novel inhibitors of Src tyrosine kinase for the treatment of bone diseases. Bioorganic & medicinal chemistry letters, 2003, Sep-15, Volume: 13, Issue:18 Novel bone-targeted 2,6,9-trisubstituted purine template-based inhibitors of Src tyrosine kinase are described. Drug design studies of known purine compounds revealed that both positions-2 and -6 were suitable for incorporating bone-seeking moieties. A variety of bone-targeting groups with different affinity to hydroxyapatite were utilized in the study. Compound 3d was determined to be a potent Src inhibitor and was quite selective against a panel of other protein kinases. Topics: Adenosine Triphosphate; Animals; Bone Diseases; Drug Delivery Systems; Drug Design; Durapatite; Enzyme Inhibitors; Humans; Inhibitory Concentration 50; Purines; src-Family Kinases; Structure-Activity Relationship	2003

Article

Year

Bone-targeted 2,6,9-trisubstituted purines: novel inhibitors of Src tyrosine kinase for the treatment of bone diseases.

Bioorganic & medicinal chemistry letters, 2003, Sep-15, Volume: 13, Issue:18

Novel bone-targeted 2,6,9-trisubstituted purine template-based inhibitors of Src tyrosine kinase are described. Drug design studies of known purine compounds revealed that both positions-2 and -6 were suitable for incorporating bone-seeking moieties. A variety of bone-targeting groups with different affinity to hydroxyapatite were utilized in the study. Compound 3d was determined to be a potent Src inhibitor and was quite selective against a panel of other protein kinases.

Topics: Adenosine Triphosphate; Animals; Bone Diseases; Drug Delivery Systems; Drug Design; Durapatite; Enzyme Inhibitors; Humans; Inhibitory Concentration 50; Purines; src-Family Kinases; Structure-Activity Relationship

2003